Status:
UNKNOWN
Functional Outcomes Following Anal Cancer Treatment
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust
Collaborating Sponsors:
The Christie NHS Foundation Trust
Bowel Disease Research Foundation
Conditions:
Anal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Anal cancer is treated with chemoradiotherapy- combined chemotherapy and radiotherapy. This is very successful (75% long term survival). During the course of the radiotherapy, other organs in the pelv...
Eligibility Criteria
Inclusion
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years or above.
- Squamous cell or basaloid carcinoma of the anal canal
Exclusion
- adenocarcinoma, melanoma, lymphoma, sarcoma or other malignancy of anal canal
- Any synchronous or metanchronous pelvic malignancy of non-anal origin (eg. prostatic, genital tract)
- unable to complete questionnaire
Key Trial Info
Start Date :
October 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2017
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT01853059
Start Date
October 1 2013
End Date
October 1 2017
Last Update
May 15 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Addenbrookes Hospital
Cambridge, United Kingdom, CB2 0QQ
2
Christie Hospital
Manchester, United Kingdom, M20 4BX